Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.10, Iss.4, 2010-04, pp. : 605-614

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The myelodysplastic syndromes

By Sekeres Mikkael A

Expert Opinion on Biological Therapy, Vol. 7, Iss. 3, 2007-03 ,pp. : 369-377

Informa Healthcare

Access to resources Recommend Favorite

Darbepoetin alfa in the treatment of chemotherapy-induced anaemia

By Wauters Isabelle Vansteenkiste Johan

Expert Opinion on Biological Therapy, Vol. 9, Iss. 2, 2009-02 ,pp. : 221-230

Informa Healthcare

Access to resources Recommend Favorite

MicroRNA Dysregulation in the Myelodysplastic Syndromes

MicroRNA, Vol. 2, Iss. 3, 2013-11 ,pp. : 174-186

Bentham Science Publishers

Access to resources Recommend Favorite

Darbepoetin alfa: a new therapy for the management of anaemia associated with chronic kidney disease

By Lindberg Jill

Expert Opinion on Biological Therapy, Vol. 2, Iss. 8, 2002-12 ,pp. : 977-984

Informa Healthcare

Access to resources Recommend Favorite

Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia

By Vansteenkiste Johan Rossi Gregory Foote MaryAnn

Expert Opinion on Biological Therapy, Vol. 3, Iss. 3, 2003-06 ,pp. : 501-508

Informa Healthcare

Access to resources Recommend Favorite